News Releases

Date Title  
06/11/18
Summary TogglePLx Pharma Inc. to Present at JMP Securities Life Sciences Conference

HOUSTON , June 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
05/11/18
Summary TogglePLx Pharma Inc. Reports First Quarter 2018 Results

HOUSTON , May 11, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
03/23/18
Summary TogglePLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
HOUSTON , March 23, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
03/15/18
Summary TogglePLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call
HOUSTON , March 15, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced
PDF Version
11/09/17
Summary TogglePLx Pharma Inc. Reports Third Quarter 2017 Results
HOUSTON , Nov. 09, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today its
PDF Version
11/02/17
Summary TogglePLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
HOUSTON , Nov. 02, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced
PDF Version
09/19/17
Summary TogglePLx Pharma Hires Key Commercial Executives in Preparation for Future Launch of Aspertec
Industry Veterans Will Support Manufacturing and Trade Sales HOUSTON , Sept. 19, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81
PDF Version
09/18/17
Summary TogglePLx Pharma Present at the Sidoti & Company Fall 2017 Conference
HOUSTON , Sept. 18, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced
PDF Version
09/13/17
Summary TogglePLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical Advisor
Dr. Deliargyris Brings More Than 25 Years of Expertise in Cardiovascular Medicine, Academia and the Biotech Industry   PLx Pharma Continues to Build Foundation for Market-Readiness of Aspertec HOUSTON , Sept. 13, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc.
PDF Version
08/10/17
Summary TogglePLx Pharma Inc. Reports Second Quarter 2017 Results
HOUSTON , Aug. 10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today
PDF Version
Displaying 21 - 30 of 41 results